Thiopurines (Azathioprine, Mercaptopurin) updated on 07-28-2025

Large for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13576
R52619		 Meyer b (Controls exposed to Anti-TNF), 2021 Large for gestational age (birth weights above the 90th percentile) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes Indications: Inflammatory Bowel disease (IBD) 1.49 [1.12;2.00]
excluded (control group) 		284/3,554   201/3,525 485 3,554
ref
S13454
R51829		 Meyer b (Controls unexposed, sick), 2021 Large for gestational age (birth weights above the 90th percentile) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes Indications: Inflammatory Bowel disease (IBD) 1.41 [1.21;1.64] 284/3,554   1,294/19,811 1,578 3,554
ref
S12246
R45447		 Coelho (Controls exposed to 5-ASA), 2011 Hypertrophy (birth weight above the 90th percentile of the standard French growth curves of Leroy and Lefort, based on birth weight and gestational term). during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No Indications: Inflammatory Bowel disease (IBD) 1.21 [0.16;9.00] C
excluded (control group) 		2/40   2/48 4 40
ref
S12195
R45442		 Coelho (Controls unexposed, sick), 2011 Hypertrophy (birth weight above the 90th percentile of the standard French growth curves of Leroy and Lefort, based on birth weight and gestational term). during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications: Inflammatory Bowel disease (IBD) 1.37 [0.12;15.89] C 2/40   1/27 3 40
ref
S6258
R45372		 Cleary (Controls unexposed, NOS), 2009 Large for Gestational age (LGA) early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Indications: Any or not specified 0.55 [0.32;0.96] 13/466   68,814/1,139,773 68,827 466
ref
Total 3 studies 0.95 [0.42;2.16] 70,408 4,060
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Meyer b (Controls unexposed, sick), 2021Meyer b, 2021 1 1.41[1.21; 1.64]1,5783,55450%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Coelho (Controls unexposed, sick), 2011Coelho, 2011 2 1.37[0.12; 15.89]3409%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Cleary (Controls unexposed, NOS), 2009Cleary, 2009 3 0.55[0.32; 0.96]68,82746641%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 81% 0.95[0.42; 2.16]70,4084,0600.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.95[0.42; 2.16]70,4084,06081%NAMeyer b (Controls unexposed, sick), 2021 Coelho (Controls unexposed, sick), 2011 Cleary (Controls unexposed, NOS), 2009 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.55[0.32; 0.95]68,827466 -NACleary (Controls unexposed, NOS), 2009 1 unexposed, sickunexposed, sick 1.41[1.21; 1.64]1,5813,5940%NAMeyer b (Controls unexposed, sick), 2021 Coelho (Controls unexposed, sick), 2011 2 Tags Adjustment   - No  - No 1.37[0.12; 15.89]340 -NACoelho (Controls unexposed, sick), 2011 1   - Yes  - Yes 0.92[0.36; 2.30]70,4054,02090%NAMeyer b (Controls unexposed, sick), 2021 Cleary (Controls unexposed, NOS), 2009 2 Indications   - Any or not specified  - Any or not specified 0.55[0.32; 0.95]68,827466 -NACleary (Controls unexposed, NOS), 2009 1   - Inflammatory Bowel disease (IBD)  - Inflammatory Bowel disease (IBD) 1.41[1.21; 1.64]1,5813,5940%NAMeyer b (Controls unexposed, sick), 2021 Coelho (Controls unexposed, sick), 2011 2 All studiesAll studies 0.95[0.42; 2.16]70,4084,06081%NAMeyer b (Controls unexposed, sick), 2021 Coelho (Controls unexposed, sick), 2011 Cleary (Controls unexposed, NOS), 2009 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12246, 13576

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.55[0.32; 0.95]68,827466 -NACleary (Controls unexposed, NOS), 2009 1 unexposed, sick controlsunexposed, sick controls 1.41[1.21; 1.64]1,5813,5940%NAMeyer b (Controls unexposed, sick), 2021 Coelho (Controls unexposed, sick), 2011 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.48[1.11; 1.98]4893,5940%NAMeyer b (Controls exposed to Anti-TNF), 2021 Coelho (Controls exposed to 5-ASA), 2011 20.510.01.0